ECOG A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel Ifosfamide and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

ECOG A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel Ifosfamide and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
99 years or below
All
Phase 3
1 Location

Brief description of study

Request for review: CIRB Authorization Agreement, see attached.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 823062

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.